These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27143257)

  • 1. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
    Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
    Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
    Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTK
    Chen JG; Liu X; Munshi M; Xu L; Tsakmaklis N; Demos MG; Kofides A; Guerrera ML; Chan GG; Patterson CJ; Meid K; Gustine J; Dubeau T; Severns P; Castillo JJ; Hunter ZR; Wang J; Buhrlage SJ; Gray NS; Treon SP; Yang G
    Blood; 2018 May; 131(18):2047-2059. PubMed ID: 29496671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
    Castillo JJ; Hunter ZR; Yang G; Treon SP
    Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
    Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
    J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
    Munshi M; Liu X; Chen JG; Xu L; Tsakmaklis N; Demos MG; Kofides A; Guerrera ML; Jimenez C; Chan GG; Hunter ZR; Palomba ML; Argyropoulos KV; Meid K; Keezer A; Gustine J; Dubeau T; Castillo JJ; Patterson CJ; Wang J; Buhrlage SJ; Gray NS; Treon SP; Yang G
    Blood Cancer J; 2020 Jan; 10(1):12. PubMed ID: 32005797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.
    Munshi M; Liu X; Kofides A; Tsakmaklis N; Guerrera ML; Hunter ZR; Palomba ML; Argyropoulos KV; Patterson CJ; Canning AG; Meid K; Gustine J; Branagan AR; Flynn CA; Sarosiek S; Castillo JJ; Wang J; Buhrlage SJ; Gray NS; Munshi NC; Anderson KC; Treon SP; Yang G
    Blood Adv; 2022 Jun; 6(11):3332-3338. PubMed ID: 35255496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
    Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
    Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 11. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
    Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
    Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
    Mondello P; Brea EJ; De Stanchina E; Toska E; Chang AY; Fennell M; Seshan V; Garippa R; Scheinberg DA; Baselga J; Wendel HG; Younes A
    JCI Insight; 2017 Mar; 2(6):e90196. PubMed ID: 28352655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.
    Liu X; Chen JG; Munshi M; Hunter ZR; Xu L; Kofides A; Tsakmaklis N; Demos MG; Guerrera ML; Chan GG; Jimenez C; Patterson CJ; Meid K; Keezer A; Castillo JJ; Treon SP; Yang G
    Blood Adv; 2020 Jan; 4(1):141-153. PubMed ID: 31935288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
    Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
    Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
    Lantermans HC; Ma F; Kuil A; van Kesteren S; Yasinoglu S; Yang G; Buhrlage SJ; Wang J; Gray NS; Kersten MJ; Treon SP; Pals ST; Spaargaren M
    Leukemia; 2024 Jul; 38(7):1570-1580. PubMed ID: 38454120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
    Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
    Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib for the treatment of Waldenström macroglobulinemia.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
    Xu L; Tsakmaklis N; Yang G; Chen JG; Liu X; Demos M; Kofides A; Patterson CJ; Meid K; Gustine J; Dubeau T; Palomba ML; Advani R; Castillo JJ; Furman RR; Hunter ZR; Treon SP
    Blood; 2017 May; 129(18):2519-2525. PubMed ID: 28235842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waldenstrom macroglobulinemia cells devoid of BTK
    Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
    Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
    Kim JH; Kim WS; Ryu K; Kim SJ; Park C
    Leuk Lymphoma; 2016; 57(6):1413-22. PubMed ID: 26699656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.